The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity.
Full Title of Study: “CTHRC1 Apromising Biomarker in Rheumatoid Arthritis Diagnosis”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: October 1, 2020
Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints. Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability . Currently, diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints , levels of acute-phase reactants such as C-reactive protein (CRP) ,erythrocyte sedimentation rate(ESR) , high titers of rheumatoid factor (RF) and high titers of antibodies against cyclic citrullinated peptide (anti-CCP) in the plasma .Of interest, CTHRC1 is a secreted modulator of Wnt signaling, which is a key regulator of joint remodeling, and promotes cell proliferation and migration. Therefore, CTHRC1 may contribute to multiple aspects of the pathogenic FLS behavior in RA and modulate processes that promote synovial hyperplasia and invasion.The expression pattern of CTHRC1 in pannus, its role in the function of FLS relevant to cartilage damage in RA, and CTHRC1's association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients
- Diagnostic Test: CTHRC1 biomarker level in rheumatoid arthritis
- measurment of levels of CTHRC1 in patients diagnosed as RA
Clinical Trial Outcome Measures
- CTHRC1 Apromising biomarker in rheumatoid arthritis diagnosis
- Time Frame: one year
- measurement of levels of CTHRC1 in rheumatoid arthritis patients
Participating in This Clinical Trial
- -Patients diagnosed as RA. – Patients ( >18)who are age and sex matched with the controls Exclusion Criteria:
. Other Rheumatologic diseases. .Patients with malignancy . .Patients with hepatic disease .
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Lobna Amer Araby Ahmed, Principal investigator – Assiut University
- Overall Contact(s)
- Lobna Amer Araby, Master, 01019313530, firstname.lastname@example.org
Myatt GL, Ecobichon DJ, Greenhalgh R. Fenitrooxon and S-methyl fenitrothion: acute toxicity and hydrolysis in mammals. Environ Res. 1975 Dec;10(3):407-14.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.